• Aucun résultat trouvé

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working aga

N/A
N/A
Protected

Academic year: 2022

Partager "A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working aga"

Copied!
1
0
0

Texte intégral

(1)

CORRECTION Open Access

Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients

hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn- Plasma) trial

Timothy Devos

1,2*

, Tatjana Geukens

1,2

, Alexander Schauwvlieghe

3

, Kevin K. Ariën

4

, Cyril Barbezange

5

,

Myriam Cleeren

1

, Veerle Compernolle

6

, Nicolas Dauby

7

, Daniël Desmecht

8

, David Grimaldi

9

, Bart N. Lambrecht

3

, Anne Luyten

10

, Piet Maes

11

, Michel Moutschen

8

, Marta Romano

5

, Lucie Seyler

12

, Michel Toungouz Nevessignsky

13

, Katleen Vandenberghe

10

, Johan van Griensven

4

, Geert Verbeke

14

, Erika Vlieghe

15

, Jean Cyr Yombi

16

,

Laurens Liesenborghs

11

, Peter Verhamme

1

and Geert Meyfroidt

1

Correction to: Trials 21, 981 (2020)

https://doi.org/10.1186/s13063-020-04876-0

Following publication of the original article [1], we were notified of a typing mistake in one of the author names.

Originally published name: Alexander Schauvlieghe.

Corrected name: Alexander Schauwvlieghe.

The original article has been corrected.

Author details

1University Hospitals Leuven (UZ Leuven), Leuven, Belgium.2Catholic University of Leuven (KU Leuven), Leuven, Belgium.3Universitair Ziekenhuis Gent, Ghent, Belgium.4Instituut voor Tropische Geneeskunde, Antwerp,

Belgium.5Sciensano, Elsene, Belgium.6Rode Kruis Vlaanderen, Mechelen, Belgium.7Universite Libre de Bruxelles Institut d‘Immunologie Medicale, Bruxelles, Belgium.8Universite de Liege, Liege, Belgium.9Universite Libre de Bruxelles, Bruxelles, Belgium.10Leuven Coordinating Centre, Leuven, Belgium.

11Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium.12Universitair Ziekenhuis Brussel, Bruxelles, Belgium.13Croix Rouge de Belgique, Bruxelles, Belgium.14Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium.15Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium.16Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.

Reference

1. Devos, et al. A randomized, multicentre, open-label phase II proof-of- concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020;21:981.https://doi.org/10.1186/s13063-020-04876-0.

© The Author(s). 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The original article can be found online athttps://doi.org/10.1186/s13063- 020-04876-0.

* Correspondence:timothy.devos@uzleuven.be

Timothy Devos, Tatjana Geukens and Alexander Schauwvlieghe are co-first authors.

1University Hospitals Leuven (UZ Leuven), Leuven, Belgium

2Catholic University of Leuven (KU Leuven), Leuven, Belgium Full list of author information is available at the end of the article Devoset al. Trials (2020) 21:1024

https://doi.org/10.1186/s13063-020-04947-2

Références

Documents relatifs

Study design: The MORE-CRT MPP PHASE II trial is a prospective, randomized, multicenter study to assess the 6-month impact of MPP programmed to mandated MPP-AS settings in

(2016) A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver

For example, the group that received 7 mg/kg throughout the trial had a lower mean age, milder Myasthenia Gravis Foundation of America disease classification scores, and lower QMG

The primary efficacy analysis com- pared the difference in day 28 all-cause mortality (num- ber of deaths until day 28/total number of observed patients in treatment group) between

To our knowledge, Bilhvax (rSh28GST adjuvanted with Alhydrogel) is the first schistosomiasis candidate vaccine to reach a phase 3 clinical trial, aiming a significant delay in

Ravaud reports personal fees and non-financial support from PFIZER, personal fees and non-financial support from BMS, personal fees and non-financial support from Roche,

Secondary outcomes included time to culture conversion measured from the first dose of ATT to the collection of the first of two consecutive negative cultures, time to

Since then, a prospective randomized clinical trial of rituximab for the treatment of refractory myositis from different origins (juvenile and adult dermatomyositis,